These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15089806)

  • 21. Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist.
    El-Ayoubi R; Menaouar A; Gutkowska J; Mukaddam-Daher S
    Br J Pharmacol; 2005 May; 145(1):50-6. PubMed ID: 15700025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rilmenidine sympatholytic activity preserves mental and orthostatic sympathetic response and epinephrine secretion].
    Esler M; Lux A; Jennings G; Hastings J; Socratous F; Lambert G
    Arch Mal Coeur Vaiss; 2004; 97(7-8):786-92. PubMed ID: 15506067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac function during mental stress: cholinergic modulation with pyridostigmine in healthy subjects.
    Sant'anna ID; de Sousa EB; de Moraes AV; Loures DL; Mesquita ET; da Nóbrega AC
    Clin Sci (Lond); 2003 Aug; 105(2):161-5. PubMed ID: 12627998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereoselective effects of (R)- and (S)-carvedilol in humans.
    Stoschitzky K; Koshucharova G; Lercher P; Maier R; Sakotnik A; Klein W; Liebmann PM; Lindner W
    Chirality; 2001 Jul; 13(7):342-6. PubMed ID: 11400186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
    Haenni A; Lithell H
    J Hypertens Suppl; 1999 Aug; 17(3):S29-35. PubMed ID: 10489096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiovascular response to mental and physical stress in hyper-reactive normotensive subjects. Beta blockade effect].
    Przybylski J; Resnik M; Corsi M; Suez V; Dervich R; Bevacqua R; Lachitiello J; Elizari M
    Medicina (B Aires); 2004; 64(5):390-4. PubMed ID: 15560538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.
    Swedberg K; Bristow MR; Cohn JN; Dargie H; Straub M; Wiltse C; Wright TJ;
    Circulation; 2002 Apr; 105(15):1797-803. PubMed ID: 11956122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antihypertensive responses elicited by central moxonidine in rats: possible role of nitric oxide.
    Moreira TS; Takakura AC; Sato MA; Menani JV; Colombari E
    J Cardiovasc Pharmacol; 2006 Jun; 47(6):780-7. PubMed ID: 16810079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure.
    Dickstein K; Manhenke C; Aarsland T; McNay J; Wiltse C; Wright T
    Int J Cardiol; 2000 Sep; 75(2-3):167-76; discussion 176-7. PubMed ID: 11077130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic I(1)-imidazoline agonism : sympathetic mechanisms in hypertension.
    Greenwood JP; Scott EM; Stoker JB; Mary DA
    Hypertension; 2000 Jun; 35(6):1264-9. PubMed ID: 10856275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators.
    Swedberg K; Bergh CH; Dickstein K; McNay J; Steinberg M
    J Am Coll Cardiol; 2000 Feb; 35(2):398-404. PubMed ID: 10676687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moxonidine and cognitive function: interactions with moclobemide and lorazepam.
    Wesnes K; Simpson PM; Jansson B; Grahnén A; Weimann HJ; Küppers H
    Eur J Clin Pharmacol; 1997; 52(5):351-8. PubMed ID: 9272403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women.
    Kujala SM; Pöyhönen-Alho M; Kaaja RJ
    Climacteric; 2014 Aug; 17(4):356-62. PubMed ID: 24099152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model.
    Van Kerckhoven R; van Veen TA; Boomsma F; Saxena PR; Schoemaker RG
    Eur J Pharmacol; 2000 May; 397(1):113-20. PubMed ID: 10844105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Central moxonidine on salivary gland blood flow and cardiovascular responses to pilocarpine.
    Moreira TS; Takakura AC; Colombari E; De Luca LA; Renzi A; Menani JV
    Brain Res; 2003 Oct; 987(2):155-63. PubMed ID: 14499959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of moxonidine on urinary electrolyte excretion and renal haemodynamics in man.
    Wiecek A; Fliser D; Nowicki M; Ritz E
    Eur J Clin Pharmacol; 1995; 48(3-4):203-8. PubMed ID: 7589042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized clinical trial of moxonidine in patients undergoing major vascular surgery.
    Bolliger D; Seeberger MD; Lurati Buse GA; Christen P; Gürke L; Filipovic M
    Br J Surg; 2007 Dec; 94(12):1477-84. PubMed ID: 17968979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients.
    Kirch W; Hutt HJ; Plänitz V
    J Clin Pharmacol; 1990 Dec; 30(12):1088-95. PubMed ID: 2273081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects.
    Macphee GJ; Howie CA; Elliott HL; Reid JL
    Br J Clin Pharmacol; 1992 Mar; 33(3):261-7. PubMed ID: 1576046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension.
    Kemme MJ; vd Post JP; Schoemaker RC; Straub M; Cohen AF; van Gerven JM
    Br J Clin Pharmacol; 2003 Jun; 55(6):518-25. PubMed ID: 12814444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.